Skip to main content
. 2018 Jan 10;5(1):215–229. doi: 10.1007/s40744-017-0092-0

Table 2.

Mean CDAI and PRO values at baseline, 6 and 12 months by disease activity groups

Overall population (N = 1570)a Disease activity group p value
Sustained remission/LDA (N = 585) Improving remission/LDA (N = 239) Worsening M/HDA (N = 190) Sustained M/HDA (N = 556)
CDAI (0–76) mean ± SD Baseline 26.8 ± 12.8 23.0 ± 11.1 26.9 ± 13.0 25.8 ± 12.9 31.0 ± 12.9 < 0.0001
6-Month 13.8 ± 12.1 4.1 ± 2.8 19.0 ± 8.5 5.9 ± 2.9 24.5 ± 11.1 < 0.0001
12-Month 12.8 ± 11.9 3.7 ± 2.9 5.5 ± 2.9 19.3 ± 9.7 23.3 ± 10.9 < 0.0001
Change in mean ± SD (N = 1570)b − 14.0 ± 14.4 − 19.3 ± 11.4 − 21.4 ± 13.7 − 6.5 ± 13.9 − 7.7 ± 13.8 < 0.0001
mHAQ (0–3) mean ± SD Baseline 0.56 ± 0.50 0.42 ± 0.45 0.54 ± 0.50 0.59 ± 0.46 0.70 ± 0.51 < 0.0001
6-Month 0.41 ± 0.46 0.19 ± 0.30 0.41 ± 0.42 0.36 ± 0.41 0.66 ± 0.51 < 0.0001
12-Month 0.40 ± 0.46 0.18 ± 0.30 0.29 ± 0.38 0.52 ± 0.51 0.64 ± 0.48 < 0.0001c
Change in mean ± SD (N = 1544)b − 0.16 ± 0.44 − 0.25 ± 0.43 − 0.25 ± 0.44 − 0.08 ± 0.47 − 0.06 ± 0.42 < 0.0001
Patient pain (0–100) mean ± SD Baseline 50.9 ± 26.9 44.3 ± 27.1 46.6 ± 26.1 55.6 ± 25.1 57.9 ± 25.7 < 0.0001
6-Month 35.9 ± 27.9 19.4 ± 20.5 40.7 ± 26.1 28.7 ± 23.6 53.6 ± 25.4 < 0.0001
12-Month 36.7 ± 28.3 19.6 ± 20.8 29.8 ± 23.7 46.1 ± 28.7 54.4 ± 24.9 < 0.0001c
Change in mean ± SD (N = 1565)b − 14.2 ± 29.8 − 24.7 ± 28.0 − 16.9 ± 29.3 − 9.5 ± 34.1 − 3.5 ± 26.2 < 0.0001
Patient fatiguea (0–100) mean ± SD Baseline 49.9 ± 29.1 41.1 ± 28.5 47.1 ± 27.4 52.4 ± 27.1 58.8 ± 28.2 < 0.0001
6-Month 41.1 ± 29.8 26.1 ± 25.0 41.7 ± 27.2 35.1 ± 27.1 57.5 ± 27.6 < 0.0001
12-Month 40.1 ± 29.9 24.3 ± 24.4 31.2 ± 26.0 48.2 ± 29.1 56.5 ± 26.9 < 0.0001c
Change in mean ± SD (N = 981)b − 9.6 ± 29.4 − 17.6 ± 28.7 − 15.3 ± 29.0 − 4.9 ± 31.3 − 1.3 ± 27.0 < 0.0001
Morning stiffness (h) mean ± SD Baseline 2.2 ± 4.3 2.0 ± 4.4 1.6 ± 2.2 2.9 ± 5.1 2.6 ± 4.6 0.0018
6-Month 1.3 ± 3.9 0.6 ± 1.8 1.7 ± 6.9 1.4 ± 3.6 2.0 ± 3.8 < 0.0001
12-Month 1.3 ± 3.3 0.6 ± 1.4 0.9 ± 2.4 1.8 ± 3.9 2.1 ± 4.4 < 0.0001
Change in mean ± SD (N = 1483)b − 1.0 ± 4.4 − 1.5 ± 4.4 − 0.7 ± 3.1 − 1.1 ± 5.3 − 0.5 ± 4.5 0.0022
PtGA (0–100) mean ± SD Baseline 49.2 ± 25.7 42.6 ± 26.4 46.3 ± 24.6 53.7 ± 22.0 55.8 ± 24.6 < 0.0001
6-Month 34.2 ± 26.7 18.2 ± 18.7 39.6 ± 24.7 26.9 ± 23.6 51.2 ± 24.6 < 0.0001
12-Month 33.8 ± 26.8 17.0 ± 18.3 24.7 ± 20.1 45.6 ± 26.1 51.4 ± 24.1 < 0.0001
Change in mean ± SD (N = 1570)b − 15.4 ± 29.7 − 25.6 ± 27.6 − 21.6 ± 27.6 − 8.1 ± 29.7 − 4.4 ± 28.2 < 0.0001
EQ-5D-3L US Index Scorea (− 0.102 to 1.0) mean ± SD Baseline 0.68 ± 0.19 0.72 ± 0.17 0.70 ± 0.17 0.66 ± 0.17 0.63 ± 0.20 < 0.0001
6-Month 0.76 ± 0.16 0.83 ± 0.14 0.74 ± 0.14 0.78 ± 0.13 0.68 ± 0.17 < 0.0001
12-Month 0.74 ± 0.18 0.83 ± 0.14 0.78 ± 0.14 0.69 ± 0.19 0.65 ± 0.18 < 0.0001c
Change in mean ± SD (N = 898)b 0.06 ± 0.19 0.10 ± 0.18 0.07 ± 0.16 0.04 ± 0.20 0.02 ± 0.20 < 0.0001

CDAI Clinical Disease Activity Index, EQ-5D-3L EuroQol-5 dimension-3 level, h hours, LDA low disease activity, mHAQ modified Health Assessment Questionnaire, M/HDA moderate or high disease activity, PRO patient-reported outcome, PtGA Patient’s Global Assessment of Disease Activity, SD standard deviation

aCounts may be reduced because of missing data for some variables (e.g., patient fatigue and EQ-5D US Index Score were not included in the Corrona RA questionnaire until October 2010)

bChange from baseline to 12 months; calculated for patients with values at both baseline and 12 months

cStatistical significance of comparisons across disease activity groups did not change after adjustment for baseline value of the corresponding outcome. Unadjusted and adjusted regression coefficients (linear) or odds ratios (ordinal logistics) estimates shown in Supplemental Tables 2 and 3